Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
Chemodex
Cabozantinib S-malate
124
CHF
CHF 124.00
In stock
CDX-C0698-M100100 mgCHF 124.00
CDX-C0698-M500500 mgCHF 516.00
CDX-C0698-G0011 gCHF 855.00
| Product Details | |
|---|---|
| Synonyms | XL184 malate; BMS907351 malate; N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (S)-2-hydroxysuccinate |
| Product Type | Chemical |
| Properties | |
| Formula |
C32H30FN3O10 |
| MW | 635.59 |
| CAS | 1140909-48-3 |
| Source/Host Chemicals | Synthetic. |
| Purity Chemicals | ≥99% (HPLC) |
| Appearance | White to off white crystalline powder. |
| Solubility | Soluble in DMSO. |
| Identity | Determined by 1H-NMR. |
| Declaration | Manufactured by Chemodex. |
| Other Product Data |
Click here for Original Manufacturer Product Datasheet |
| InChi Key | HFCFMRYTXDINDK-WNQIDUERSA-N |
| Smiles | O=C(C1(CC1)C(NC2=CC=C(F)C=C2)=O)NC(C=C3)=CC=C3OC4=CC=NC5=CC(OC)=C(OC)C=C54.O=C(O)C[C@H](O)C(O)=O |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | +4°C |
| Handling Advice | Protect from light and moisture. |
| Use/Stability | Stable for at least 2 years after receipt when stored at +4°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Description
The s-malate salt form of Cabozantinib is very potent orally available inhibitor of multiple receptor tyrosine kinases (RTK), specifically MET and VEGFR2. It also inhibits KIT, FLT3, Tie-2, RET and AXL. Cabozantinib shows dose-dependent inhibition of tumor growth and tumor regression, associated with disruption of the tumor vasculature, angiogenesis and extensive tumor cell apoptosis.
Product References
(1) R. Kurzrock, et al.; J. Clin. Oncol. 29, 2660 (2011) | (2) M. Yakes, et al.; Mol. Cancer Ther. 10, 2298 (2011) | (3) C. Hage, et al.; Cell Death Dis. 4, e627 (2013) | (4) F. Bentzien, et al.; Thyroid. 23, 1569 (2013) | (5) Y. Sun, et al.; Med. Sci. Monit. 21, 2316 (2015) | (6) J.N. Markowitz & K.M. Fancher; Pharmacotherapy 38, 357 (2018) | (7) C. Gruellich; Recent Results Cancer Res. 211, 67 (2018)